Dose finding study for the use of subcutaneous recombinant interleukin-2 to augment natural killer cell numbers in an outpatient setting for stage 4 neuroblastoma after megatherapy and autologous stem-cell reinfusion

Journal of Clinical Oncology

Volumn 29, Issue 4, 2011, Pages 441-448

  Ladenstein, Ruth ^a   Pötschger, Ulrike ^a   Siabalis, Dimitris ^a   Garaventa, Alberto ^a   Bergeron, Christophe ^a   Lewis, Ian J ^a   Stein, Jerry ^a   Kohler, Janice ^a   Shaw, Peter J ^a   Holter, Wolfgang ^a   Pistoia, Vito ^a   Michon, Jean ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ABDOMINAL PAIN; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL COUNT; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FOOT PAIN; GRANULOCYTOPENIA; HUMAN; IMMUNOMODULATION; INGUINAL PAIN; MALE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NEUROBLASTOMA; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTOPENIA; URTICARIA;

AMBULATORY CARE; ANTINEOPLASTIC AGENTS; AUSTRALIA; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; ISRAEL; KAPLAN-MEIER ESTIMATE; KILLER CELLS, NATURAL; MALE; NEOPLASM STAGING; NEUROBLASTOMA; RECOMBINANT PROTEINS; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 79952090734     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.5465     Document Type: Article

References (54)

1. London WB, Castleberry RP, Matthay KK, et al: Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 23:6459-6465, 2005 (Pubitemid 46190236)
2. Stram DO, Matthay KK, O'Leary M, et al: Consolidation chemoradiotherapy and autologous bonemarrowtransplantation versus continuedchemotherapy for metastatic neuroblastoma: A report of two concurrent Children's Cancer Group studies. J Clin Oncol 14:2417-2426, 1996 (Pubitemid 26300106)
3. Frappaz D, Michon J, Coze C, et al: LMCE3 treatment strategy: Results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol 18:468-476, 2000 (Pubitemid 30078528)
4. Pritchard J, Cotterill SJ, Germond SM, et al: High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer 44:348-357, 2005 (Pubitemid 40316027)
5. Ladenstein R, Philip T, Lasset C, et al: Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: A report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 16:953-965, 1998 (Pubitemid 28108728)
6. Pearson AD, Pinkerton CR, Lewis IJ, et al: High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: A randomised trial. Lancet Oncol 9:247-256, 2008 (Pubitemid 351722944)
7. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid: Children's Cancer Group. N Engl J Med 341:1165-1173, 1999 (Pubitemid 29480654)
8. Berthold F, Boos J, Burdach S, et al: Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: A randomised controlled trial. Lancet Oncol 6:649-658, 2005 (Pubitemid 41222755)
9. Marti F, Pardo N, Peiro M, et al: Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation. Exp Hematol 23:1445-1452, 1995 (Pubitemid 26034076)
10. Welte K, Keever CA, Levick J, et al: Interleukin-2 production and response to interleukin-2 by peripheral blood mononuclear cells from patients after bone marrow transplantation: II. Patients receiving soybean lectin-separated and T cell-depleted bone marrow. Blood 70: 1595-1603, 1987
11. Keever CA, Welte K, Small T, et al: Interleukin 2-activated killer cells in patients following transplants of soybean lectin-separated and E rosette-depleted bone marrow. Blood 70:1893-1903, 1987
12. Janossy G, Prentice HG, Grob JP, et al: T lymphocyte regeneration after transplantation of T cell depleted allogeneic bone marrow. Clin Exp Immunol 63:577-586, 1986 (Pubitemid 16128996)
13. Hercend T, Takvorian T, Nowill A, et al: Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. Blood 67:722-728, 1986 (Pubitemid 16130263)
14. Dilloo D, Laws HJ, Hanenberg H, et al: Induction of two distinct natural killer-cell populations, activated T cells and antineoplastic cytokines, by interleukin-2 therapy in children with solid tumors. Exp Hematol 22:1081-1088, 1994 (Pubitemid 24314774)
15. Soiffer RJ, Murray C, Cochran K, et al: Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 79:517-526, 1992
16. Phillips JH, Lanier LL: Dissection of the lymphokine-activated killer phenomenon: Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 164:814-825, 1986 (Pubitemid 16024836)
17. Zeng Y, Huebener N, Fest S, et al: Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. Cancer Res 67:2331-2338, 2007 (Pubitemid 46424254)
18. Rueda F, Marti F, Pardo N, et al: Interleukin-2 in neuroblastoma: Clinical perspectives based on biological studies. Cancer Biotherapy Radiopharmaceuticals 11:303-308, 1996 (Pubitemid 27008582)
19. Zhang SR, Salup RR, Urias PE, et al: Augmentation of NK activity and/or macrophage-mediated cytotoxicity in the liver by biological response modifiers including human recombinant interleukin 2. Cancer Immunol Immunother 21:19-25, 1986 (Pubitemid 16232078)
20. Pardo N, Marti F, Fraga G, et al: High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: Pilot study. Med Pediatr Oncol 27: 534-539, 1996 (Pubitemid 26365298)
21. Favrot MC, Floret D, Negrier S, et al: Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation. Bone Marrow Transplant 4:499-503, 1989 (Pubitemid 19236581)
22. Michon J, Negrier S, Coze C, et al: Administration of high-dose recombinant interleukin 2 after autologous bone marrow transplantation in patients with neuroblastoma: Toxicity, efficacy and survival: A Lyon-Marseille-Curie-east of France Group Study. Prog Clin Biol Res 385:293-300, 1994
23. Negrier S, Michon J, Floret D, et al: Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma. J Clin Oncol 9:1363-1370, 1991
24. Pession A, Prete A, Locatelli F, et al: Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma. Br J Cancer 78:528-533, 1998 (Pubitemid 28360644)
25. Toren A, Nagler A, Rozenfeld-Granot G, et al: Amplification of immunological functions by subcutaneous injection of intermediate-high dose interleukin-2 for 2 years after autologous stem cell transplantation in children with stage IV neuroblastoma. Transplantation 70: 1100-1104, 2000
26. Valteau-Couanet D, Rubie H, Meresse V, et al: Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma. Bone Marrow Transplant 16:515-520, 1995
27. Margolin KA, Rayner AA, Hawkins MJ, et al: Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J Clin Oncol 7:486-498, 1989 (Pubitemid 19098144)
28. Atzpodien J, Lopez Hanninen E, Kirchner H, et al: Multi-institutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13:497-501, 1995
29. Guida M, Abbate I, Casamassima A, et al: Long-term subcutaneous recombinant interleukin-2 as maintenance therapy: Biological effects and clinical implications. Cancer Biotherapy 10:195-203, 1995
30. Meropol NJ, Porter M, Blumenson LE, et al: Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity. Clin Cancer Res 2:669-677, 1996 (Pubitemid 26133469)
31. Palmer PA, Atzpodien J, Philip T, et al: A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma. Cancer Biotherapy 8:123-136, 1993 (Pubitemid 23300240)
32. Schomburg A, Kirchner H, Lopez-Hanninen E, et al: Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha: Evidence of a risk-benefit advantage of subcutaneous therapy. Am J Clin Oncol 17:199-209, 1994 (Pubitemid 24160608)
33. Angevin E, Valteau-Couanet D, Farace F, et al: Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer. J Immunother Emphasis Tumor Immunol 18:188-195, 1995 (Pubitemid 26016525)
34. Recchia F, Saggio G, Cesta A, et al: Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer. Cancer Immunol Immunother 56:699-708, 2007 (Pubitemid 46348737)
35. Lansky SB, List MA, Lansky LL, et al: The measurement of performance in childhood cancer patients. Cancer 60:1651-1656, 1987 (Pubitemid 17141022)
36. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993 (Pubitemid 23228250)
37. Ambros IM, Benard J, Boavida M, et al: Quality assessment of genetic markers used for therapy stratification. J Clin Oncol 21:2077-2084, 2003 (Pubitemid 46606355)
38. Meropol NJ, Barresi GM, Fehniger TA, et al: Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous lowdose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol Immunother 46:318-326, 1998 (Pubitemid 28410578)
39. Soori G, Dillman RO, Wiemann MC, et al: Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: Final results of cancer biotherapy research group 94-10. Cancer Biotherapy and Radiopharmaceuticals 17:165-173, 2002 (Pubitemid 34507416)
40. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981 (Pubitemid 11167383)
41. Coze C, Hartmann O, Michon J, et al: NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: A report from the French Society of Pediatric Oncology. J Clin Oncol 15:3433-3440, 1997 (Pubitemid 27527714)
42. Kushner BH, LaQuaglia MP, Bonilla MA, et al: Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 12:2607-2613, 1994 (Pubitemid 24379646)
43. Ladenstein R, Favrot M, Lasset C, et al: Indication and limits of megatherapy and bone marrow transplantation in high-risk neuroblastoma: A single centre analysis of prognostic factors. Eur J Cancer 29A:947-956, 1993 (Pubitemid 23126690)
44. Miano M, Garaventa A, Pizzitola MR, et al: Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. Bone Marrow Transplant 27:571-574, 2001 (Pubitemid 32401452)
45. Shafford EA, Rogers DW, Pritchard J: Advanced neuroblastoma: Improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26. J Clin Oncol 2:742-747, 1984 (Pubitemid 14050679)
46. Tweddle DA, Pinkerton CR, Lewis IJ, et al: OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age. Med Pediatr Oncol 36:239-242, 2001
47. Valteau-Couanet D, Benhamou E, Vassal G, et al: Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma. Bone Marrow Transplant 25:937-942, 2000 (Pubitemid 30255725)
48. Valteau-Couanet D, Michon J, Boneu A, et al: Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J Clin Oncol 23:532-540, 2005 (Pubitemid 46224230)
49. Blaise D, Olive D, Stoppa AM, et al: Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 76:1092-1097, 1990 (Pubitemid 20318151)
50. Gilman AL, Ozkaynak MF, Matthay KK, et al: Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: A report from the Children's Oncology Group. J Clin Oncol 27:85-91, 2009
51. Yu AL, Gilman AL, Ozkaynak MF, et al: Anti- GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363: 1324-1334, 2010
52. Recchia F, De Filippis S, Rosselli M, et al: Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease: A phase II study. Int J Oncol 20:1275-1282, 2002
53. Zeng Y, Fest S, Kunert R, et al: Antineuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol 42:1311-1319, 2005 (Pubitemid 40798947)
54. Hank JA, Gan J, Ryu H, et al: Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma. Clin Cancer Res 15:5923-5930, 2009